Efficacy and immune cell profile (determined by flow cytometry and IHC) were evaluated in CloudmanS91 and MC38 syngeneic murine tumor models following treatment with ALRN-6924 alone and in combination with anti-PD-1 or anti-PD-L1, including re-challenge studies to test for immunological memory. This evidence concerns the gene RPL17 and neoplasm.